Pluri Inc. (NasdaqCM: PLUR)
Health Care · Biotechnology · IL
$0.93
-2.44% today · -78.1% 1Y
Pluri Inc. (NasdaqCM: PLUR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $11.48M and employs 92 people.
Over the last twelve months the share price has lost 78.1%, trading between 0.85 and 4.87.
Tweenvest scores Pluri Inc. across four factors: quality 11/100, value 53/100. Its strongest factor is value.
PLUR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.48M
- Revenue (TTM)
- $1.02M
- P/E
- —
- EPS
- -2.44
- Dividend yield
- —
- Beta (5Y)
- 0.69
- 52-week high
- $4.87
- 52-week low
- $0.85
- Avg volume (3M)
- —
- Shares outstanding
- 12.34M
- Employees
- 92
- Next earnings
- —
About Pluri Inc.
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
- ISIN
- US72942G2030
- Founded
- 2001
- Listed since
- Jun 30, 2003
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AEON Biopharma, Inc.NYSEAM: AEON | $11.57M | $0.23 | -15.94% |
| BioLineRx Ltd.TASE: BLRX | $11.56M | ₪0.01 | -7.69% |
| Eagle Pharmaceuticals, Inc.OTCPK: EGRX | $11.53M | $0.89 | -8.76% |
| Aelis Farma SAENXTPA: AELIS | $11.50M | €0.75 | -5.88% |
| Celyad Oncology SAENXTBR: CYAD | $11.43M | €0.23 | +13.50% |
| NGeneBio Co., Ltd.KOSDAQ: A354200 | $11.31M | ₩937.00 | +18.91% |
| Pharmigene, Inc.TPEX: 7595 | $11.28M | NT$7.25 | -2.03% |
| Passage Bio, Inc.NasdaqCM: PASG | $11.26M | $3.50 | -5.15% |
Figures last refreshed Oct 18, 2026.